BOSTON (TheStreet) -- The number of prescriptions written for MannKind's (MNKD) inhaled insulin drug Afrezza have barely made a dent in the diabetes market since partner Sanofi (SNY) launched the product five months ago.
Afrezza is even underperforming Exubera, the first inhaled insulin drug, launched by Pfizer in 2006. Exubera was a commercial failure, forcing Pfizer (PFE) to abandon the product after one year.
Here's a graphical representation of just how badly MannKind's Afrezza is performing relative to other diabetes drugs.
The three lines clustered tightly together at the bottom of the chart represent the number of Afrezza prescriptions written weekly since launched in early February, as reported by healthcare data providers IMS Health and Bloomberg (Symphony).
The light blue line with the "X" hashmarks represents the number of prescriptions written for Exubera at the start of its launch in 2006. Afrezza prescriptions today are lagging behind that track. MannKind claims Afrezza is superior in every way to Exubera, and therefore should succeed where Exubera failed. However, almost five months into its launch, MannKind's promise rings hollow.
The purple line in the chart zooming into orbit tracks prescriptions written for Tanzeum, a GLP-1 injection marketed by GlaxoSmithKline (GSK). Tanzeum isn't insulin, but it's included in this comparison because it helps illustrate Sanofi's poor job marketing Afrezza.